Obsace-ER 50mg Tablet contains Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) indicated primarily for the treatment of obsessive-compulsive disorder (OCD) and major depressive disorder (MDD). Fluvoxamine functions by inhibiting the reuptake of serotonin in the central nervous system, thereby increasing serotonin levels and enhancing neurotransmission, which contributes to mood regulation and reduction of obsessive-compulsive symptoms. The extended-release formulation of Obsace-ER allows for once-daily dosing, improving patient compliance and maintaining steady plasma drug concentrations. It is typically prescribed for adults and adolescents over 18 years, with dosage adjustments based on clinical response and tolerability. Common adverse effects may include nausea, headache, insomnia, and somnolence, while serious side effects, although rare, can involve serotonin syndrome, suicidal ideation, and hypersensitivity reactions. Caution is advised when co-administered with monoamine oxidase inhibitors (MAOIs), other serotonergic agents, or anticoagulants due to potential drug interactions. Patients with a history of bipolar disorder or seizures should be monitored closely. Regular follow-up is recommended to assess therapeutic efficacy and adverse effects. Obsace-ER should be used under medical supervision, with gradual dose titration and discontinuation to minimize withdrawal symptoms.